Literature DB >> 17877918

Immunization for atherosclerosis.

Kuang-Yuh Chyu1, Jan Nilsson, Prediman K Shah.   

Abstract

This review summarizes experimental findings that highlight the complex roles of the immune system in atherogenesis. Immune activation can have either proatherogenic or atheroprotective effects. Immune-modulation therapy via an active or passive immunization strategy aims to exploit the atheroprotective aspects of the immune system to modulate atherosclerosis. Several experimental studies have demonstrated that such an approach is feasible and effective, raising the tantalizing possibility that an atheroprotective vaccine can be developed for clinical testing. Several potential immunogens have been identified and tested for their atheroprotective efficacy with variable results. Although several questions such as choice of optimal antigens, choice of most effective adjuvants, the optimal route of administration, durability of effects, and safety remain to be answered, we believe that a vaccine-based approach to manage atherosclerotic cardiovascular disease is a potentially viable paradigm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17877918     DOI: 10.1007/s11883-007-0005-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  64 in total

1.  Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein.

Authors:  S GERO; J GERGELY; L JAKAB; J SZEKELY; S VIRAG; K FARKAS; A CZUPPON
Journal:  Lancet       Date:  1959-07-04       Impact factor: 79.321

2.  Autism and MMR vaccination in North London; no causal relationship.

Authors:  B Taylor; R Lingam; A Simmons; J Stowe; E Miller; N Andrews
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

3.  The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice.

Authors:  A Daugherty; E Puré; D Delfel-Butteiger; S Chen; J Leferovich; S E Roselaar; D J Rader
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL.

Authors:  X H Xu; P K Shah; E Faure; O Equils; L Thomas; M C Fishbein; D Luthringer; X P Xu; T B Rajavashisth; J Yano; S Kaul; M Arditi
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

5.  Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation.

Authors:  Peter Friedman; Sohvi Horkko; Daniel Steinberg; Joseph L Witztum; Edward A Dennis
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

6.  B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice.

Authors:  Amy S Major; Sergio Fazio; MacRae F Linton
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

7.  ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5.

Authors:  S Patel; E M Thelander; M Hernandez; J Montenegro; H Hassing; C Burton; S Mundt; A Hermanowski-Vosatka; S D Wright; Y S Chao; P A Detmers
Journal:  Biochem Biophys Res Commun       Date:  2001-08-10       Impact factor: 3.575

8.  Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice.

Authors:  Jose R Faria-Neto; Kuang-Yuh Chyu; Xiaojun Li; Paul C Dimayuga; Carmel Ferreira; Juliana Yano; Bojan Cercek; Prediman K Shah
Journal:  Atherosclerosis       Date:  2006-01-18       Impact factor: 5.162

9.  Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL.

Authors:  Christoph J Binder; Sohvi Hörkkö; Asheesh Dewan; Mi-Kyung Chang; Emily P Kieu; Carl S Goodyear; Peter X Shaw; Wulf Palinski; Joseph L Witztum; Gregg J Silverman
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

10.  Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity.

Authors:  S E Roselaar; G Schonfeld; A Daugherty
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more
  2 in total

Review 1.  Anti-inflammatory therapies for cardiovascular disease.

Authors:  Paul M Ridker; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2014-05-26       Impact factor: 29.983

2.  Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J mice.

Authors:  Min Xia; Daxin Chen; Valeria Endresz; Ildiko Lantos; Andrea Szabo; Vijay Kakkar; Xinjie Lu
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.